Endocrinology Book

Information Resources


Euglycemic Ketoacidosis

Aka: Euglycemic Ketoacidosis
  1. See Also
    1. SGLT Inhibitor
    2. Diabetic Ketoacidosis
    3. Metabolic Acidosis with Anion Gap
  2. Epidemiology: SGLT2 Inhibitor Associated Ketosis
    1. Initially 73 reported cases in 2 years for patients on SGLT2 Inhibitors with Serum Glucose <250 mg/dl
    2. Subsequently 2500 cases with patients on SGLT2 Inhibitors reported to FDA
      1. Fadini (2017) Diebetologia 60(8): 1385-9 [PubMed]
  3. Mechanism: SGLT2 Inhibitor Associated Ketosis
    1. Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2 Inhibitor) are Oral Hypoglycemic agents in Type II Diabetes
    2. SGLT2 Inhibitors block Glucose reabsorption in the Kidneys, with Glucose excreted in the urine
    3. Results in lower Blood Sugars, results in decreased Insulin release
    4. May result in increased Fatty Acid breakdown and Ketone production due to Hypoglycemia
      1. SGLT2 Inhibitor may also directly increase Fatty Acid breakdown and Ketone production
  4. Risk Factors: SGLT2 Inhibitor Associated Ketosis
    1. Increased risk with renal Impairment (as well as Dehydration, acute illness)
      1. Avoid Farxiga (Dapagliflozin) if GFR <60 ml/min
      2. Avoid Invokana (Canagliflozin) and Jardiance (Empagliflozin) if GFR <45 ml/min
  5. Symptoms
    1. Onset as early as first 2 weeks of starting an SGLT2 Inhibitors
    2. Nausea and Vomiting
    3. Fatigue
  6. Signs
    1. Dehydration
    2. Tachypnea
    3. Sinus Tachycardia
    4. Confusion
  7. Labs
    1. Metabolic Acidosis with Anion Gap
    2. Serum Ketones increased (but Urine Ketones often normal)
    3. Serum Glucose paradoxically normal
  8. Differential Diagnosis
    1. See Metabolic Acidosis with Anion Gap
    2. Diabetic Ketoacidosis
    3. Alcohol Ketoacidosis
    4. Starvation Ketoacidosis
    5. Pregnancy
    6. Sepsis
    7. Pancreatitis
  9. Management: SGLT2 Inhibitor Associated Ketosis
    1. Similar management as with Diabetic Ketoacidosis Management
    2. Initiate fluid bolus
    3. Start D10 infusion
    4. Start Insulin 0.1 units/kg/h infusion (do not give Insulin bolus)
      1. Confirm normal Potassium before initiating Insulin
  10. Resources
    1. FDA
      1. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
  11. References
    1. Swaminathan and Hayes in Herbert (2019) EM:Rap 19(6): 12

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree